Valuation: argenx SE

Market Cap 52.43B 45.53B 42.45B 39B 73.75B 4,988B 74.56B 500B 196B 2,493B 197B 193B 8,261B P/E 2026 *
30.6x
P/E 2027 * 24.7x
Enterprise Value 47.24B 41.02B 38.25B 35.13B 66.45B 4,494B 67.18B 451B 176B 2,246B 177B 174B 7,443B EV / Sales 2026 *
7.64x
EV / Sales 2027 * 5.91x
Free-Float
99.98%
Yield 2026 *
0.05%
Yield 2027 * 0.1%
1 day+1.15%
1 week-5.05%
Current month-1.15%
1 month-9.42%
3 months+8.52%
6 months+2.85%
Current year+2.73%
1 week 717.4
Extreme 717.4
770
1 month 717.4
Extreme 717.4
832
Current year 568.4
Extreme 568.4
833.6
1 year 544.2
Extreme 544.2
833.6
3 years 271
Extreme 271
833.6
5 years 224.1
Extreme 224.1
833.6
10 years 12.5
Extreme 12.5
833.6
Manager TitleAgeSince
Chief Executive Officer 47 2026-05-05
Director of Finance/CFO 56 2021-05-31
Chief Tech/Sci/R&D Officer - 2014-12-31
Director TitleAgeSince
Chairman 54 2026-05-05
Director/Board Member 76 2015-05-12
Director/Board Member 65 2016-04-27
Date Insider Type Main position Quantity % Market Cap.
11/23/25 Sell

Director

4,680 0.0076%
11/23/25 Fiscal year

Director

4,680 0.0076%
11/23/25 Fiscal year

Chief Executive Officer

2,000 0.0032%
Change 5-day change 1-year change 3-year change Capi.($)
+1.21%-5.05%+22.94%+66.57% 52.43B
+10.00%+14.90%+53.89%+87.07% 62.53B
-0.98%-1.19%-16.98%-14.21% 23.1B
+0.30%-5.17%-11.23%+349.07% 21.4B
-0.32%+0.40%+30.99%-26.23% 17.76B
+4.29%+8.97%+200.03%+341.85% 15.47B
+1.29%-1.93%+12.70%+607.25% 14.68B
+1.71%-0.90%+52.13%+176.27% 14.08B
+4.16%+4.44%+444.12%+183.06% 12.62B
+5.30%-5.80%+62.62%+160.98% 11.73B
Average +2.70%+0.31%+85.12%+193.17% 24.58B
Weighted average by Cap. +3.62%+1.47%+60.39%+148.47%

Financials

2026 *2027 *
Net sales 6.18B 5.37B 5.01B 4.6B 8.7B 588B 8.79B 59.02B 23.07B 294B 23.22B 22.71B 974B 7.59B 6.59B 6.15B 5.65B 10.68B 722B 10.8B 72.46B 28.33B 361B 28.51B 27.89B 1,196B
Net income 1.85B 1.6B 1.49B 1.37B 2.6B 176B 2.62B 17.61B 6.88B 87.73B 6.93B 6.78B 291B 2.46B 2.13B 1.99B 1.83B 3.45B 234B 3.49B 23.44B 9.16B 117B 9.22B 9.02B 387B
Net Debt -5.19B -4.51B -4.2B -3.86B -7.3B -494B -7.38B -49.55B -19.37B -247B -19.49B -19.07B -818B -7.57B -6.58B -6.13B -5.63B -10.65B -720B -10.77B -72.29B -28.26B -360B -28.44B -27.82B -1,193B
Logo argenx SE
argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises.
Employees
1,863
Date Price Change Volume
26-08-05 736.80 +1.21% 7,016
26-08-04 €728.00 +0.80% 89,773
26-08-03 €722.20 -3.06% 94,348
26-07-31 €745.00 -0.21% 96,817
26-07-30 €746.60 -3.74% 97,191
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
838.42USD
Average target price
1,036.47USD
Spread / Average Target
+23.62%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ARGX Stock